Page last updated: 2024-08-24

zileuton and mk 287

zileuton has been researched along with mk 287 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cai, X; Eckman, J; Hussoin, MS; Hwang, SB; Ip, SH; Killian, DB; Libertine-Garahan, L; Qian, C; Scannell, RT; Shen, TY; Yaeger, D; Yeh, CG	1

Other Studies

1 other study(ies) available for zileuton and mk 287

Article	Year
(+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a potent dual 5-lipoxygenase inhibitor and platelet-activating factor receptor antagonist. Journal of medicinal chemistry, 1998, May-21, Volume: 41, Issue:11 Topics: Animals; Arachidonic Acid; Blood Platelets; Cell Membrane; CHO Cells; Cricetinae; Drug Evaluation, Preclinical; Edema; Enzyme Inhibitors; Furans; Hematocrit; Humans; Leukotriene B4; Lipoxygenase Inhibitors; Mice; Platelet Membrane Glycoproteins; Rats; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Structure-Activity Relationship; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured; Urea	1998

Article

Year

(+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a potent dual 5-lipoxygenase inhibitor and platelet-activating factor receptor antagonist.

Journal of medicinal chemistry, 1998, May-21, Volume: 41, Issue:11

Topics: Animals; Arachidonic Acid; Blood Platelets; Cell Membrane; CHO Cells; Cricetinae; Drug Evaluation, Preclinical; Edema; Enzyme Inhibitors; Furans; Hematocrit; Humans; Leukotriene B4; Lipoxygenase Inhibitors; Mice; Platelet Membrane Glycoproteins; Rats; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Structure-Activity Relationship; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured; Urea

1998